Research programme: ROR gamma modulators - Amgen/Teijin Pharma

Drug Profile

Research programme: ROR gamma modulators - Amgen/Teijin Pharma

Alternative Names: ROR-gamma modulators - Amgen/Teijin Pharma

Latest Information Update: 12 Aug 2013

Price : $50

At a glance

  • Originator Amgen; Teijin Pharma
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 31 Jul 2013 Early research in Autoimmune disorders in USA and Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top